

Akinobu Tawada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10739041/publications.pdf>

Version: 2024-02-01

74
papers

1,421
citations

304368

22
h-index

344852

36
g-index

74
all docs

74
docs citations

74
times ranked

2104
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. <i>Oncology</i> , 2014, 87, 330-341.	0.9	161
2	Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2015, 33, 1257-1262.	1.2	75
3	Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. <i>Investigational New Drugs</i> , 2015, 33, 729-739.	1.2	75
4	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. <i>PLoS ONE</i> , 2014, 9, e84807.	1.1	70
5	Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. <i>Liver International</i> , 2011, 31, 1013-1020.	1.9	64
6	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. <i>Hepatology</i> , 2018, 67, 575-585.	3.6	57
7	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. <i>Investigational New Drugs</i> , 2020, 38, 172-180.	1.2	57
8	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 382-396.	4.2	54
9	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. <i>Investigational New Drugs</i> , 2018, 36, 332-339.	1.2	52
10	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 155-162.	4.5	44
11	Autoimmune fulminant liver failure in adults: Experience in a Japanese center. <i>Hepatology Research</i> , 2011, 41, 133-141.	1.8	43
12	Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3638-3647.	1.1	40
13	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. <i>Investigational New Drugs</i> , 2016, 34, 255-260.	1.2	40
14	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 21315-21326.	0.8	39
15	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1197-1204.	1.4	36
16	A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>PLoS ONE</i> , 2015, 10, e0125244.	1.1	34
17	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 906.	1.8	28
18	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 473-484.	4.2	28

#	ARTICLE	IF	CITATIONS
19	Interferon- β induced PD-L1 expression and soluble PD-L1 production in gastric cancer. <i>Oncology Letters</i> , 2020, 20, 2161-2168.	0.8	28
20	Current and future directions for treating hepatitis B virus infection. <i>World Journal of Hepatology</i> , 2015, 7, 1541.	0.8	26
21	Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3335-3342.	1.1	25
22	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
23	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2014, 11, 707-712.	1.1	21
24	Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2014, 34, 4231-7.	0.5	21
25	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 5303.	1.6	20
26	Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2014, 39, 262-268.	2.0	19
27	Fatal Diaphragmatic Hernia following Radiofrequency Ablation for Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2015, 8, 238-245.	0.3	18
28	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. <i>Hepatology International</i> , 2016, 10, 574-593.	1.9	18
29	Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 908-915.	1.4	15
30	Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170153.	1.1	15
31	Biological features and biomarkers in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 2020.	0.8	12
32	Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. <i>International Journal of Medical Sciences</i> , 2016, 13, 310-315.	1.1	11
33	Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. <i>Biology</i> , 2017, 6, 30.	1.3	11
34	Successful Interventional Treatment for Arterioportal Fistula Caused by Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2014, 7, 833-839.	0.3	10
35	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
36	Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Oncology</i> , 2016, 90, 199-208.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. <i>Hepatology International</i> , 2013, 7, 144-152.	1.9	8
38	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2021, 12, 2694-2701.	1.2	8
39	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 703-713.	1.9	7
40	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161303.	1.1	7
41	Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan. <i>Hepatology International</i> , 2013, 7, 1030-1039.	1.9	6
42	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0163119.	1.1	6
43	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21560-21568.	0.8	6
44	Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2015, 35, 549-54.	0.5	6
45	Intracranial Metastasis in a Patient with Hepatocellular Carcinoma and Gastric Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 199-203.	0.3	5
46	Simultaneous chylous ascites and chylothorax during ramucirumab plus docetaxel chemotherapy in a patient with non-small lung cell cancer. <i>International Cancer Conference Journal</i> , 2019, 8, 114-117.	0.2	5
47	Contrasting functions of the epithelial-stromal interaction 1 gene, in human oral and lung squamous cell cancers. <i>Oncology Reports</i> , 2021, 47, .	1.2	5
48	Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	4
49	Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α -2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype. <i>Case Reports in Gastroenterology</i> , 2015, 9, 215-220.	0.3	4
50	Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4853-4858.	1.0	4
51	Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 363-370.	0.6	4
52	Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E161-2.	1.8	3
53	Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2017, 56, 3041-3045.	0.3	3
54	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. <i>World Journal of Gastroenterology</i> , 2015, 21, 8888.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2013, 33, 5603-9.	0.5	3
56	A case of hepatocellular carcinoma with spontaneous regression of a tumor thrombus invading the main portal trunk. <i>Acta Hepatologica Japonica</i> , 2016, 57, 178-185.	0.0	2
57	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. <i>Acta Hepatologica Japonica</i> , 2017, 58, 647-653.	0.0	2
58	Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study. <i>Oncology Letters</i> , 2022, 23, .	0.8	2
59	¹⁸ F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis. <i>International Medical Case Reports Journal</i> , 2014, 7, 103.	0.3	1
60	A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration. <i>Acta Hepatologica Japonica</i> , 2015, 56, 469-476.	0.0	1
61	Two patients with hepatic mucosa-associated lymphoid tissue lymphoma resembling hypervascular hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 536-539.	0.0	1
62	Successful treatment of three elderly patients aged 80-90 years with hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 628-631.	0.0	1
63	Successful treatment of two patients with hepatocellular carcinoma exhibiting severe pancytopenia caused by aplastic anemia. <i>Acta Hepatologica Japonica</i> , 2016, 57, 557-560.	0.0	1
64	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. <i>Acta Hepatologica Japonica</i> , 2021, 62, 25-32.	0.0	1
65	Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	1
66	Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine. <i>Acta Hepatologica Japonica</i> , 2015, 56, 213-216.	0.0	0
67	Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. <i>Case Reports in Gastroenterology</i> , 2017, 11, 29-35.	0.3	0
68	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. <i>Acta Hepatologica Japonica</i> , 2017, 58, 176-182.	0.0	0
69	Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. <i>International Journal of Medical Sciences</i> , 2017, 14, 1088-1093.	1.1	0
70	Approaching the tumor microenvironment in patients with advanced hepatocellular carcinoma using needle biopsy samples. <i>Journal of Clinical Oncology</i> , 2021, 39, 334-334.	0.8	0
71	Current status of medical oncology in Japan and changes over the most recent 7-year period: results of a questionnaire sent to designated cancer care hospitals. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1622-1627.	0.6	0
72	A case of Takotsubo cardiomyopathy after microwave ablation therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 548-554.	0.0	0

#	ARTICLE	IF	CITATIONS
73	Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2021, 62, 656-662.	0.0	0
74	A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 346-346.	0.8	0